Drug-Eluting Stent Benefits Do Not Outweigh Price Tag – Lancet Study
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stent use could be restricted to certain high-risk patient subgroups until the price of the stents is reduced, according to a cost-effectiveness study presented Sept. 6 at the European Society of Cardiology meeting in Stockholm